Clinical study on administration of erythropoietin in patients with acute myocardial infarction
- VernacularTitle:促红细胞生成素用于急性心肌梗死的临床观察
- Author:
Haipeng GUO
;
Yongsheng SONG
;
Qizhu TANG
- Publication Type:Journal Article
- Keywords:
Acute myocardial infarction;
Erythropeictin;
Thrombolytic therapy;
Apoptosis
- From:
Clinical Medicine of China
2008;24(8):772-774
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of erythropoietin on cardiac function of the patients with acute mycardial infarction (AMI). Methods 48 patients with AMI successfully treated with thrombolytic therapy were randomized into two group,2000 units of recombinant human erytfu-opoietin(rh-EPO) were administrated once a time in therapeutic group,3 times on alternate days in one week and total for 4 weeks. The peak value of serum creatine kinase(CK) and creatinkinase isozyme MB (CK-MB)were measured, myocardial infarct size (S) was estimated by Hindmen's QRS scoring system, and the diameter of left ventricular end diastolic(LVEDd) and left ventricular injection fraction (LVEF) were determined with echocardiography at the 4th weekend in both groups. Results CK, CKMB and S in therapeutic group were lower than in control group (P < 0.05). LVEDd and LVEF were also improved in the therapeutic group. Conclusion rh-EPO can significantly lessen the size of isehemia and infarct myocardium, mitigate the infarction degree and improve the cardiac function slightly in AMI patients.
